Device for transdermal administration for the treatment of urinary tract disorders
申请人:SCHWARZ PHARMA AG
公开号:EP1293198A1
公开(公告)日:2003-03-19
This invention provides a device containing a compound of formula (I)
wherein
R represents a saturated or unsaturated C2-7 aliphatic acyl group optionally substituted by one or more halogen atoms, a hydroxy group, a C1-6 alkoxy group, a carboxyl group, a C2-7 alkoxycarbonyl group, a 5 to 7-membered cycloalkyl group, a phenyl or naphthyl group; a C2-6 hydroxyalkyl group; an aliphatic acyloxyalkyl group having a C2-7 acyl group and a C1-6 alkyl group; a C1-6 alkyl group substituted by a C1-6 alkoxy group, a carboxyl group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl group substituted by a phenyl or naphthyl group, a carbamoyl group, a mono- or di-(C1-6 alkyl)-substituted carbamoyl group or a cyano group; a benzoyl or naphthoyl group optionally substituted by one or more halogen atoms; a furoyl group or a pyridylcarbonyl group; and
R1 represents a C1-6 alkyl group optionally substituted by one or more halogen atoms, a phenyl or a naphthyl group;
the carbon atom marked "*" represents a carbon atom in (R)-configuration, (S)-configuration or a mixture thereof.
The TTS is efficient in the treatment of urinary tract disorders, such as benign prostatic hypertrophy.
本发明提供了一种含有式(I)化合物的装置
其中
R 代表饱和或不饱和的 C2-7 脂肪族酰基,可任选被一个或多个卤素原子、羟基、C1-6 烷氧基、羧基、C2-7 烷氧基羰基、5 至 7 元环烷基、苯基或萘基取代;C2-6 羟基烷基;具有 C2-7 丙烯酸基和 C1-6 烷基的脂肪族酰氧基烷基;被 C1-6 烷氧基、羧基、C2-7 烷氧基羰基、被苯基或萘基取代的 C2-7 烷氧基羰基、氨基甲酰基、单-或二-(C1-6 烷基)取代的氨基甲酰基或氰基取代的 C1-6 烷基;任选被一个或多个卤素原子取代的苯甲酰基或萘甲酰基;呋喃基或吡啶羰基;和
R1 代表任选被一个或多个卤素原子取代的 C1-6 烷基、苯基或萘基;
标有 "*"的碳原子代表(R)-构型、(S)-构型的碳原子或它们的混合物。
TTS 可有效治疗泌尿系统疾病,如良性前列腺肥大。